Haifeng Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haifeng Lu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Gang Chen
Institute of Stroke Research, Soochow University, Suzhou, China; Department of Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China
5 shared publications- Hongru Zhao
Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China
4 shared publications Jiajie Lu
Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
4 shared publicationsJianqiang Ni
First Affiliated Hospital of Soochow University
4 shared publicationsHaitao Shen
Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
3 shared publicationsHaiying Li
Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
3 shared publications
Latest Publications
- Open Access
Association of time of day at stroke onset with functional outcomes after reperfusion therapy in acute ischaemic stroke: a retrospective cohort study in China
Objectives: To investigate the association between the time of day of stroke onset and functional outcomes among patients with acute ischaemic stroke who received reperfusion therapy. Design: Retrospective cohort study. Setting: Patients with acute ischaemic stroke who received reperfusion therapy (intravenous thrombolysis or combined endovascular therapy) between October 2018 and March 2022 in China were included. Participants: A total of 712 patients with acute ischaemic stroke receiving reperfusion therapy were included. Patients were categorised into two groups (day-onset (06:00–18:00) and night-onset (18:00–06:00)) and into six groups by 4-hour intervals. Outcome measures: The primary outcome was the 3-month functional status, evaluated using the modified Rankin Scale, with scores of 0–2 classified as favourable and scores of 3–6 as unfavourable outcomes. Propensity score matching (PSM), inverse probability of treatment weighting (IPTW) and overlap weighting (OW) were used for analyses. Results: 148 out of 286 patients (51.7%) in the night-onset group and 182 out of 426 patients (42.7%) in the day-onset group experienced unfavourable outcomes at 3 months. Night-onset stroke was associated with a significantly higher risk of unfavourable outcome compared with day-onset stroke (OR 1.44 (95% CI 1.06 to 1.94), p=0.018). This association remained significant after adjustment using PSM (OR 1.45 (95% CI 1.01 to 2.08), p=0.044), and was further confirmed in analyses using IPTW (OR 1.42 (95% CI 1.02 to 1.96), p=0.036), OW (OR 1.42 (95% CI 1.03 to 1.96), p=0.032) and multivariable adjustment (adjusted OR 1.55 (95% CI 1.07 to 2.22), p=0.019). Night-onset stroke during 22:00–02:00 (adjusted OR 2.44 (95% CI 1.34 to 4.43), p=0.003) was significantly associated with a higher likelihood of unfavourable outcome in adjusted analysis. Conclusions: Night-onset stroke was associated with poorer functional outcomes at 3 months among patients receiving reperfusion therapy. Further multicentre prospective studies are warranted to validate these findings. Trial registration number: Chinese Clinical Trial Registry Identifier: ChiCTR2500101844.
Open AccessAssociation of time of day at stroke onset with functional outcomes after reperfusion therapy in acute ischaemic stroke: a retrospective cohort study in China
Objectives: To investigate the association between the time of day of stroke onset and functional outcomes among patients with acute ischaemic stroke who received reperfusion therapy. Design: Retrospective cohort study. Setting: Patients with acute ischaemic stroke who received reperfusion therapy (intravenous thrombolysis or combined endovascular therapy) between October 2018 and March 2022 in China were included. Participants: A total of 712 patients with acute ischaemic stroke receiving reperfusion therapy were included. Patients were categorised into two groups (day-onset (06:00–18:00) and night-onset (18:00–06:00)) and into six groups by 4-hour intervals. Outcome measures: The primary outcome was the 3-month functional status, evaluated using the modified Rankin Scale, with scores of 0–2 classified as favourable and scores of 3–6 as unfavourable outcomes. Propensity score matching (PSM), inverse probability of treatment weighting (IPTW) and overlap weighting (OW) were used for analyses. Results: 148 out of 286 patients (51.7%) in the night-onset group and 182 out of 426 patients (42.7%) in the day-onset group experienced unfavourable outcomes at 3 months. Night-onset stroke was associated with a significantly higher risk of unfavourable outcome compared with day-onset stroke (OR 1.44 (95% CI 1.06 to 1.94), p=0.018). This association remained significant after adjustment using PSM (OR 1.45 (95% CI 1.01 to 2.08), p=0.044), and was further confirmed in analyses using IPTW (OR 1.42 (95% CI 1.02 to 1.96), p=0.036), OW (OR 1.42 (95% CI 1.03 to 1.96), p=0.032) and multivariable adjustment (adjusted OR 1.55 (95% CI 1.07 to 2.22), p=0.019). Night-onset stroke during 22:00–02:00 (adjusted OR 2.44 (95% CI 1.34 to 4.43), p=0.003) was significantly associated with a higher likelihood of unfavourable outcome in adjusted analysis. Conclusions: Night-onset stroke was associated with poorer functional outcomes at 3 months among patients receiving reperfusion therapy. Further multicentre prospective studies are warranted to validate these findings. Trial registration number: Chinese Clinical Trial Registry Identifier: ChiCTR2500101844.
- 17 August 2022
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 68, 104127
Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
- 17 August 2022
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 68, 104127
Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
- Open Access
- 1 July 2022
- Published by Medknow in Medical Gas Research
- Vol. 12 (3) , 73-76
Current research progress of isoflurane in cerebral ischemia/reperfusion injury
Cerebral ischemia/reperfusion injury is an important factor leading to poor prognosis in ischemic stroke patients. Therefore, it is particularly important to find effective remedial measures to promote the health of patients to return to society. Isoflurane is a safe and reliable anesthetic gas with a long history of clinical application. In recent years, its protection function to human body has been widely recognized, and nowadays isoflurane for cerebral protection has been widely studied, and the stable effect of isoflurane has satisfied many researchers. Basic studies have shown that isoflurane’s protection of brain tissue after ischemia/reperfusion involves a variety of signaling pathways and effector molecules. Even though many signaling pathways have been described, more and more studies focus on exploring their mechanisms of action, in order to provide strong evidence for clinical application. This could prompt the introduction of isoflurane therapy to clinical patients as soon as possible. In this paper, several confirmed signaling pathways will be reviewed to find possible strategies for clinical treatment.
- 1 July 2022
- Published by Medknow in Medical Gas Research
- Vol. 12 (3) , 73-76
Open AccessCurrent research progress of isoflurane in cerebral ischemia/reperfusion injury
Cerebral ischemia/reperfusion injury is an important factor leading to poor prognosis in ischemic stroke patients. Therefore, it is particularly important to find effective remedial measures to promote the health of patients to return to society. Isoflurane is a safe and reliable anesthetic gas with a long history of clinical application. In recent years, its protection function to human body has been widely recognized, and nowadays isoflurane for cerebral protection has been widely studied, and the stable effect of isoflurane has satisfied many researchers. Basic studies have shown that isoflurane’s protection of brain tissue after ischemia/reperfusion involves a variety of signaling pathways and effector molecules. Even though many signaling pathways have been described, more and more studies focus on exploring their mechanisms of action, in order to provide strong evidence for clinical application. This could prompt the introduction of isoflurane therapy to clinical patients as soon as possible. In this paper, several confirmed signaling pathways will be reviewed to find possible strategies for clinical treatment.
- Open Access
- 1 January 2022
- Published by Elsevier in Neuroscience
- Vol. 481, 60-72
MicroRNA-133b-3p Targets Purinergic P2X4 Receptor to Regulate Central Poststroke Pain in Rats
- 1 January 2022
- Published by Elsevier in Neuroscience
- Vol. 481, 60-72
Open AccessMicroRNA-133b-3p Targets Purinergic P2X4 Receptor to Regulate Central Poststroke Pain in Rats
- Open Access
- 28 October 2021
- Published by Springer Nature in Research Square
Stargazin Interaction With Serine Racemase Mediates Cerebral Ischemia/Reperfusion Injury in Rats
D-Serine is thought to be involved in N-methyl-D-aspartate (NMDA)-type glutamate receptor-mediated neurotoxicity and plays a pathophysiologic role in stroke. D-Serine is synthesized by serine racemase (SR), which directly converts L-serine into D-serine. The deletion of SR has been reported to protect against cerebral ischemia damage. Additionally, SR catalytic activity is physiologically regulated by its binding to stargazin. However, whether the stargazin-SR interaction affects the level of stroke damage remains elusive. We showed that cerebral ischemia increased the interaction of stargazin and SR and decreased the levels of D-serine. Disrupting the stargazin-SR interaction by knocking down stargazin aggravated cerebral ischemic insults. We found that cerebral ischemia decreased the phosphorylation of stargazin at the Thr-321 residue, which was phosphorylated by cAMP-dependent protein kinase A (PKA). Treatment with the PKA inhibitor H89 blocked stargazin T321 phosphorylation, augmented the stargazin-SR interaction, decreased D-serine levels, and alleviated focal cerebral ischemic damage in rats subjected to middle cerebral artery occlusion and reperfusion (MCAO/R). Thus, the stargazin-SR interaction is a promising strategy in the treatment of stroke.
- 28 October 2021
- Published by Springer Nature in Research Square
Open AccessStargazin Interaction With Serine Racemase Mediates Cerebral Ischemia/Reperfusion Injury in Rats
D-Serine is thought to be involved in N-methyl-D-aspartate (NMDA)-type glutamate receptor-mediated neurotoxicity and plays a pathophysiologic role in stroke. D-Serine is synthesized by serine racemase (SR), which directly converts L-serine into D-serine. The deletion of SR has been reported to protect against cerebral ischemia damage. Additionally, SR catalytic activity is physiologically regulated by its binding to stargazin. However, whether the stargazin-SR interaction affects the level of stroke damage remains elusive. We showed that cerebral ischemia increased the interaction of stargazin and SR and decreased the levels of D-serine. Disrupting the stargazin-SR interaction by knocking down stargazin aggravated cerebral ischemic insults. We found that cerebral ischemia decreased the phosphorylation of stargazin at the Thr-321 residue, which was phosphorylated by cAMP-dependent protein kinase A (PKA). Treatment with the PKA inhibitor H89 blocked stargazin T321 phosphorylation, augmented the stargazin-SR interaction, decreased D-serine levels, and alleviated focal cerebral ischemic damage in rats subjected to middle cerebral artery occlusion and reperfusion (MCAO/R). Thus, the stargazin-SR interaction is a promising strategy in the treatment of stroke.
- 1 August 2021
- Published by Elsevier in The Journal of Pain
- Vol. 22 (8) , 968-980
P2X4R Contributes to Central Disinhibition Via TNF-α/TNFR1/GABAaR Pathway in Post-stroke Pain Rats
- 1 August 2021
- Published by Elsevier in The Journal of Pain
- Vol. 22 (8) , 968-980
P2X4R Contributes to Central Disinhibition Via TNF-α/TNFR1/GABAaR Pathway in Post-stroke Pain Rats
- Open Access
- 3 May 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
Background: The previously approved botulinum toxin and nowadays promising calcitonin gene-related peptide (CGRP) monoclonal antibody have shown efficacy for preventing chronic migraine (CM). However, there is no direct evidence for their relative effectiveness and safety. In this study, we conducted an indirect treatment comparison to compare the efficacy and safety of CGRP monoclonal antibody with botulinum toxin for the preventive treatment of chronic migraine.Methods: Up to August 31, 2020, we systematically searched PubMed, Embase, and Cochrane Library Central Register of Controlled Trials (Central). Weighted mean difference (WMD) and relative risk (RR) were used to evaluate clinical outcomes. Indirect treatment comparison (ITC) software was used to conduct indirect treatment comparison.Results: Ten studies were pooled with 6,325 patients in our meta-analysis. Both botulinum toxin and CGRP monoclonal antibody demonstrated favorable efficacy in the change of migraine days, headache days, HIT-6 score, and 50% migraine responder rate compared with placebo. In indirect treatment comparison, CGRP monoclonal antibody was superior to botulinum toxin in the frequency of acute analgesics intake (WMD = −1.31, 95% CI: −3.394 to 0.774, p = 0.02113), the rate of treatment-related adverse events (AEs) (RR = 0.664, 95% CI: 0.469 to 0.939, p = 0.04047), and the rate of treatment-related serious adverse events (RR = 0.505, 95% CI: 0.005 to 46.98, p < 0.001).Conclusion: For chronic migraine patients, CGRP monoclonal antibody was slightly better than botulinum toxin in terms of efficacy and safety. In the future, head-to-head trials would be better to evaluate the efficacy and safety between different medications in the prevention of chronic migraine.
- 3 May 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessCalcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
Background: The previously approved botulinum toxin and nowadays promising calcitonin gene-related peptide (CGRP) monoclonal antibody have shown efficacy for preventing chronic migraine (CM). However, there is no direct evidence for their relative effectiveness and safety. In this study, we conducted an indirect treatment comparison to compare the efficacy and safety of CGRP monoclonal antibody with botulinum toxin for the preventive treatment of chronic migraine.Methods: Up to August 31, 2020, we systematically searched PubMed, Embase, and Cochrane Library Central Register of Controlled Trials (Central). Weighted mean difference (WMD) and relative risk (RR) were used to evaluate clinical outcomes. Indirect treatment comparison (ITC) software was used to conduct indirect treatment comparison.Results: Ten studies were pooled with 6,325 patients in our meta-analysis. Both botulinum toxin and CGRP monoclonal antibody demonstrated favorable efficacy in the change of migraine days, headache days, HIT-6 score, and 50% migraine responder rate compared with placebo. In indirect treatment comparison, CGRP monoclonal antibody was superior to botulinum toxin in the frequency of acute analgesics intake (WMD = −1.31, 95% CI: −3.394 to 0.774, p = 0.02113), the rate of treatment-related adverse events (AEs) (RR = 0.664, 95% CI: 0.469 to 0.939, p = 0.04047), and the rate of treatment-related serious adverse events (RR = 0.505, 95% CI: 0.005 to 46.98, p < 0.001).Conclusion: For chronic migraine patients, CGRP monoclonal antibody was slightly better than botulinum toxin in terms of efficacy and safety. In the future, head-to-head trials would be better to evaluate the efficacy and safety between different medications in the prevention of chronic migraine.
- Open Access
- 15 August 2020
- Published by Springer Nature in Molecular Brain
- Vol. 13 (1) , 1-15
TMEM175 mediates Lysosomal function and participates in neuronal injury induced by cerebral ischemia-reperfusion
As the main organelles for the clearance of damaged proteins and damaged organelles, the function of lysosomes is crucial for maintaining the intracellular homeostasis of long-lived neurons. A stable acidic environment is essential for lysosomes to perform their functions. TMEM175 has been identified as a new K+channel that is responsible for regulating lysosomal membrane potential and pH stability in neurons. This study aimed to understand the role of TMEM175 in lysosomal function of neurons and neuronal injury following cerebral ischemia-reperfusion (I/R). A middle-cerebral-artery occlusion/reperfusion (MCAO/R) model was established in adult male Sprague-Dawley rats in vivo, and cultured neurons were exposed to oxygen-glucose deprivation/reoxygenation (OGD/R) to mimic ischemia-reperfusion (I/R) injury in vitro. We found that the protein level of TMEM175 decreased after cerebral I/R injury and that TMEM175 overexpression ameliorated MCAO/R-induced brain-cell death and neurobehavioral deficits in vivo. Furthermore, these results were recapitulated in cultured neurons. Acridine orange (AO) staining, as well as LysoSensor Green DND-189, cathepsin-B (CTSB), and cathepsin-D (CTSD) activities, showed that TMEM175 deficiency inhibited the hydrolytic function of lysosomes by affecting lysosomal pH. In contrast, TMEM175 upregulation reversed OGD/R-induced lysosomal dysfunction and impaired mitochondrial accumulation in cultured neurons. TMEM175 deficiency induced by cerebral I/R injury leads to compromised lysosomal pH stability, thus inhibiting the hydrolytic function of lysosomes. Consequently, lysosomal-dependent degradation of damaged mitochondria is suppressed and thereby exacerbates brain damage. Exogenous up-regulation of TMEM175 protein level could reverse the neuronal lysosomal dysfunction after ischemia-reperfusion.
- 15 August 2020
- Published by Springer Nature in Molecular Brain
- Vol. 13 (1) , 1-15
Open AccessTMEM175 mediates Lysosomal function and participates in neuronal injury induced by cerebral ischemia-reperfusion
As the main organelles for the clearance of damaged proteins and damaged organelles, the function of lysosomes is crucial for maintaining the intracellular homeostasis of long-lived neurons. A stable acidic environment is essential for lysosomes to perform their functions. TMEM175 has been identified as a new K+channel that is responsible for regulating lysosomal membrane potential and pH stability in neurons. This study aimed to understand the role of TMEM175 in lysosomal function of neurons and neuronal injury following cerebral ischemia-reperfusion (I/R). A middle-cerebral-artery occlusion/reperfusion (MCAO/R) model was established in adult male Sprague-Dawley rats in vivo, and cultured neurons were exposed to oxygen-glucose deprivation/reoxygenation (OGD/R) to mimic ischemia-reperfusion (I/R) injury in vitro. We found that the protein level of TMEM175 decreased after cerebral I/R injury and that TMEM175 overexpression ameliorated MCAO/R-induced brain-cell death and neurobehavioral deficits in vivo. Furthermore, these results were recapitulated in cultured neurons. Acridine orange (AO) staining, as well as LysoSensor Green DND-189, cathepsin-B (CTSB), and cathepsin-D (CTSD) activities, showed that TMEM175 deficiency inhibited the hydrolytic function of lysosomes by affecting lysosomal pH. In contrast, TMEM175 upregulation reversed OGD/R-induced lysosomal dysfunction and impaired mitochondrial accumulation in cultured neurons. TMEM175 deficiency induced by cerebral I/R injury leads to compromised lysosomal pH stability, thus inhibiting the hydrolytic function of lysosomes. Consequently, lysosomal-dependent degradation of damaged mitochondria is suppressed and thereby exacerbates brain damage. Exogenous up-regulation of TMEM175 protein level could reverse the neuronal lysosomal dysfunction after ischemia-reperfusion.
- Open Access
- 15 April 2020
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 14, 341
Temporal Patterns of Vertigo and Migraine in Vestibular Migraine
Vestibular migraine (VM) is a multidisciplinary disease under exploration. Multiple temporal patterns of vertigo and migraine make it difficult to diagnose VM, and their effect on the clinical features of VM is still unclear. Here we investigated the clinical features of VM under three temporal patterns. 172 VM patients were enrolled in this study and divided into three groups: 86 patients in group A had an earlier onset of migraine than vertigo, 35 patients in group B had an earlier onset of vertigo than migraine, and 51 patients in group C had concurrent vertigo and migraine. No significant difference was found among three groups regarding types, intensity and accompanying symptoms of the vestibular attack. Patients in group C presented higher frequency and longer duration of vertigo than group A and B, while patients in group A presented lower frequency and shorter duration of headaches than group B and C. Additionally, the frequency, duration, intensity and accompanying symptoms of headache in group A decreased significantly after the onset of vertigo, especially in women around menopause. We hypothesized that vestibular stimulation could inhibit the trigeminal pain pathway, while painful trigeminal stimulation could excite the vestibular system. Our findings may contribute to the clinical identification of VM and further clarification of its pathogenesis.
- 15 April 2020
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 14, 341
Open AccessTemporal Patterns of Vertigo and Migraine in Vestibular Migraine
Vestibular migraine (VM) is a multidisciplinary disease under exploration. Multiple temporal patterns of vertigo and migraine make it difficult to diagnose VM, and their effect on the clinical features of VM is still unclear. Here we investigated the clinical features of VM under three temporal patterns. 172 VM patients were enrolled in this study and divided into three groups: 86 patients in group A had an earlier onset of migraine than vertigo, 35 patients in group B had an earlier onset of vertigo than migraine, and 51 patients in group C had concurrent vertigo and migraine. No significant difference was found among three groups regarding types, intensity and accompanying symptoms of the vestibular attack. Patients in group C presented higher frequency and longer duration of vertigo than group A and B, while patients in group A presented lower frequency and shorter duration of headaches than group B and C. Additionally, the frequency, duration, intensity and accompanying symptoms of headache in group A decreased significantly after the onset of vertigo, especially in women around menopause. We hypothesized that vestibular stimulation could inhibit the trigeminal pain pathway, while painful trigeminal stimulation could excite the vestibular system. Our findings may contribute to the clinical identification of VM and further clarification of its pathogenesis.